MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Primary demo goals have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, while among the exploratory objectives https://jonahk665xit8.celticwiki.com/user